YOKNEAM, Israel, Nov. 5, 2012 /PRNewswire/ -- Syneron Medical Ltd.
(NASDAQ: ELOS), www.syneron.com, the leading global aesthetic
device company, announced today that Hugo
Goldman has been appointed Chief Financial Officer,
effective immediately. Mr. Goldman replaces David Schlachet, who had been serving as interim
Chief Financial Officer since August
2012.
(Logo: http://photos.prnewswire.com/prnh/20120528/535447
)
Prior to joining Syneron, Mr. Goldman served as Chief Financial
Officer of Retalix, Ltd., a leading global provider of software and
services to high volume, high complexity retailers, that is
dual-listed on the NASDAQ and Tel Aviv Stock Exchanges. During his
tenure at Retalix, Mr. Goldman played a key role in helping Retalix
to grow and improve profitability while developing and successfully
executing a growth strategy for the future. He was
instrumental in enhancing its global financial strengths and
operating efficiencies and has extensive experience with the
finance and investment communities.
From 2000 to 2007, Mr. Goldman was Chief Financial Officer at
AxisMobile (listed on the AIM stock exchange in London), VocalTec Communications Ltd. (listed
on the NASDAQ stock exchange) and Algorithmic Research Ltd.
(subsidiary of NASDAQ listed company). From 1983 to 1999, he held
several finance positions of increasing responsibility in
Israel and the United States at Motorola Semiconductor
(now Freescale Semiconductor Inc.), ultimately reaching the
position Chief Financial Officer of the Company's Israeli
operations. Mr. Goldman began his career at the accounting firm
Kesselman & Kesselman (now PricewaterhouseCoopers).
Mr. Goldman holds a bachelor's degree in Accounting and
Economics from the University of Tel-Aviv and an Executive MBA from Bradford
University with distinction. He is a certified public accountant in
Israel.
Louis P. Scafuri, Chief Executive
Officer of Syneron, said, "We are pleased to welcome Hugo Goldman to the Syneron team. He has served
as Chief Financial Officer of several global publicly traded
companies, which has given him extensive experience in the areas of
finance, business development, compliance, financial reporting and
investor relations. He has also had responsibilities with
information technology, logistics, human resources and legal
departments, giving him a broad array of operational expertise. We
believe he is ideally suited to help achieve our goal to continue
driving growth while also improving our operating leverage and
profitability profile."
Michael Anghel, member of
Syneron's Board of Directors and Chairman of the Company's Audit
Committee, commented, "Hugo Goldman
has a strong professional background with a track record of working
closely with senior management and board members to design and
implement successful operational strategies. He also has deep
experience in financial reporting and compliance, which should
allow for a smooth transition as he joins the Company."
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real technology,
real science and real results – is the leading global aesthetic
device company with a comprehensive product portfolio and a global
distribution footprint. The Company's technology enables
physicians to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite.
The Company sells its products under two distinct brands, Syneron
and Candela. The Company's aspiration and commitment to
innovation expands Syneron's offering beyond medical device into
the largest in-demand applications in beauty - skin
lightening. Founded in 2000, the corporate, R&D, and
manufacturing headquarters for Syneron Medical Ltd. are located in
Israel. Syneron also has R&D
and manufacturing operations in the US. The company markets
and services and supports its products in 86 countries. It has
offices in North America,
France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide. Additional information can be found at
www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the company
will not meet stated goals, as well as the risks set forth in
Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and
the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
Contacts:
Hugo Goldman, Chief Financial
Officer
Email: hugo.goldman@syneron.com
Zack Kubow, The Ruth Group
646-536-7020
Email: zkubow@theruthgroup.com
SOURCE Syneron Medical Ltd.